0001594062-17-000101.txt : 20170608 0001594062-17-000101.hdr.sgml : 20170608 20170508104239 ACCESSION NUMBER: 0001594062-17-000101 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLABMART INC. CENTRAL INDEX KEY: 0001689084 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 813623646 STATE OF INCORPORATION: WY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 777 BRICKELL AVENUE STREET 2: SUITE 500 CITY: MIAMI STATE: FL ZIP: 33131 BUSINESS PHONE: 7866202140 MAIL ADDRESS: STREET 1: 1900 PURDY AVENUE STREET 2: #1907 CITY: MIAMI BEACH STATE: FL ZIP: 33139 CORRESP 1 filename1.htm

 
BIOLAB MART INC.
777 Brickell Avenue
Suite 500
Miami, Florida 33131


                   May 8, 2017

BY EDGAR

Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E.
Washington, D.C. 20549-7010
Attention:  Suzanne Hayes
Assistant Director
Office of Healthcare and Insurance


Re: BioLab Mart Inc.
Registration Statement on Form S-1 (File Number 333-216650)

Dear Ms. Hayes:

In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended (the "Act"), BioLab Mart Inc. (the "Company") hereby requests that the Registration Statement described above (the "Registration Statement") be accelerated so that it will become effective at 3:00 p.m. on Wednesday, May 10, 2017, or as soon as practicable thereafter. In connection with such request, the undersigned hereby acknowledges the following:

1. Should the Securities and Exchange Commission (the "Commission") or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing.

2. The action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing.

3. The Company may not assert staff comments or the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Should you have any questions regarding this matter, please do not hesitate to call Nancy Brenner, Esq., counsel for the Company at (917) 282-4272, email address nbrenneresq@gmail.com.

Thank you for your attention to this matter.

  
 
 
Very truly yours,


/s/Jonah Meer
Jonah Meer
Chief Executive Officer



cc: Nancy Brenner, Esq.